IMB Dx is a precision oncology company focused on developing solutions for safe & accurate cancer diagnosis & monitoring. We created AlphaLiquid®, a minimally-invasive liquid biopsy method which requires only a single blood draw to detect cancer and monitor its progress. With AlphaLiquid®, we offer a comprehensive genomic profile of the tumor and matching therapies as well as clinical trial information. Since we began our research in 2014, our goal has remained the same: to make cancer diagnosis accessible and affordable to as many cancer patients as possible. For more information, please visit us at www.imbdx.com/eng/ or contact us at support@imbdx.com.